High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses  by Uebelhoer, Luke S. et al.
Antiviral Research 106 (2014) 86–94Contents lists available at ScienceDirect
Antiviral Research
journal homepage: www.elsevier .com/locate /ant iv i ra lHigh-throughput, luciferase-based reverse genetics systems
for identifying inhibitors of Marburg and Ebola virusesqhttp://dx.doi.org/10.1016/j.antiviral.2014.03.018
0166-3542/Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
q The ﬁndings and conclusions in this report are ours and do not necessarily
represent the views of the Centers for Disease Control and Prevention.
⇑ Corresponding author. Tel.: +1 404 6394561.
E-mail address: jit8@cdc.gov (J.S. Towner).
1 Denotes equal contribution by authors.Luke S. Uebelhoer 1, César G. Albariño 1, Laura K. McMullan, Ayan K. Chakrabarti, Joel P. Vincent,
Stuart T. Nichol, Jonathan S. Towner ⇑
Centers for Disease Control and Prevention, Atlanta, USA
a r t i c l e i n f o a b s t r a c tArticle history:
Received 6 December 2013
Revised 28 March 2014
Accepted 29 March 2014
Available online 5 April 2014
Keywords:
Filovirus
Marburg virus
Ebola virus
Luciferase
Reverse genetics
Antiviral screenMarburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae, represent a signiﬁcant
challenge to global public health. Currently, no licensed therapies exist to treat ﬁlovirus infections, which
cause up to 90% mortality in human cases. To facilitate development of antivirals against these viruses,
we established two distinct screening platforms based on MARV and EBOV reverse genetics systems that
express secreted Gaussia luciferase (gLuc). The ﬁrst platform is a mini-genome replicon to screen viral
replication inhibitors using gLuc quantiﬁcation in a BSL-2 setting. The second platform is complementary
to the ﬁrst and expresses gLuc as a reporter gene product encoded in recombinant infectious MARV and
EBOV, thereby allowing for rapid quantiﬁcation of viral growth during treatment with antiviral
compounds. We characterized these viruses by comparing luciferase activity to virus production, and
validated luciferase activity as an authentic real-time measure of viral growth. As proof of concept, we
adapt both mini-genome and infectious virus platforms to high-throughput formats, and demonstrate
efﬁcacy of several antiviral compounds. We anticipate that both approaches will prove highly useful in
the development of anti-ﬁlovirus therapies, as well as in basic research on the ﬁlovirus life cycle.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).1. Introduction
Marburg virus (MARV) and Ebola virus (EBOV) are members of
the family Filoviridae, and cause severe and often fatal hemorrhagic
fevers in humans (Feldmann and Geisbert, 2011; US Centers for
Disease Control and Prevention, 2013). The genomes of ﬁloviruses
are 19 kb, single-stranded, negative sense RNA molecules encod-
ing a total of 7 genes (NP, VP35, VP40, GP, VP30, VP24, L) separated
by intergenic regions of varying lengths and ﬂanked by untrans-
lated regions (UTRs) at the 30 and 50 ends (Feldmann et al., 2013)
(Fig. 1A).
Since the identiﬁcation of MARV in 1967 and EBOV in 1976,
signiﬁcant ﬁlovirus research has focused on developing antiviral
therapies. However, despite promising vaccine candidates, no
licensed prophylactics currently exist for preventing or treating
ﬁlovirus infections. Screening libraries of chemical inhibitors has
proven to be an excellent approach, including treatments thattarget RNA replication using subgenomic (mini-genome) systems
(Hoenen et al., 2011; Jasenosky et al., 2010). However, as such
systems do not recapitulate the entire viral life cycle, antiviral
effects must be conﬁrmed using infectious virus. Previous efforts
using infectious virus have utilized GFP or RFP-expressing EBOV
(Ebihara et al., 2007; Towner et al., 2005) and MARV (Schmidt
et al., 2011; Schudt et al., 2013), sometimes in conjunction with
high-content imaging (Panchal et al., 2010, 2012). During the
preparation of this manuscript, a novel EBOV expressing Fireﬂy
luciferase (fLuc) was reported (Hoenen et al., 2013). Although not
adapted to a high-throughput format, this system allows for rapid
quantiﬁcation of viral replication by measuring intracellular fLuc
expression.
Here, we present two complementary methods (dual-platform)
that could substantially improve the ability to screen for potential
MARV and EBOV inhibitors. The ﬁrst platform utilizes a mini-
genome replicon that expresses the Gaussia luciferase (gLuc)
reporter gene, a protein that, unlike fLuc, is secreted directly into
the cell-culture media making for easy, repetitive, and non-
destructive quantitation of mini-genome replication. Further, this
platform is non-infectious and can be handled in BSL-2 laboratories
common in most university and pharmaceutical industry settings.
The second platform uses recombinant infectious MARV and EBOV
Fig. 1. Construction and optimization of ﬁlovirus gLuc mini-genomes. (A) Schematic of the basic ﬁlovirus genome in anti-genome (viral complementary) sense, depicting 7
viral genes separated by intergenic regions and ﬂanked by 50 and 30 UTRs. (B) Schematic of mini-genome and viral support protein plasmids used to drive the gLuc mini-
genome systems. The gLuc reporter gene was cloned in genomic (viral) sense between 50 and 30 UTRs of MARV (Genbank FJ750958) or EBOV (Genbank NC_002549). Solid lines
indicate ﬁlovirus UTRs, and dashed lines indicate pCAGGS plasmid sequence. (C) Codon optimization of gLuc mini-genomes. BSR-T7/5 cells were transfected with MARV or
EBOV gLuc mini-genome plasmid and corresponding wild-type (circles, left graphs) or codon-optimized (squares, right graphs) support plasmids pC-NP, pC-VP35, pC-VP30,
and pC-L. Parallel transfections were carried out using empty expression vector (pCAGGS) containing no virus polymerase sequence as a control (open symbols). Data is
representative of 3 independent experiments, with mean and standard error of the mean (SEM) of luciferase expression from 3 wells displayed for each time point in relative
light units (RLUs).
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ruses can be reliably rescued and propagated to high titers, and
that luciferase expression is a faithful representation of virus
growth. Although restricted to BSL-4 containment, these gLuc-re-
porter viruses can serve as a stand-alone option for screening
inhibitors of all stages of the viral life cycle. Both platforms can
be easily adapted to high-throughput (96-well) formats. Finally,
we demonstrate the utility of both platforms by screening several
known and unknown ﬁlovirus inhibitors, and ﬁnd that 6azaU, a
compound that inhibits de novo pyrimidine biosynthesis (Hands-
chumacher, 1960), inhibits both MARV and EBOV mini-genome
replication and infectious virus growth.2. Materials and methods
2.1. Cell culture and biosafety
BSR-T7/5, BHK-21, and Vero-E6 cells were propagated in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
5% fetal bovine serum (FBS) and 1% penicillin–streptomycin (Invit-
rogen). BSR-T7/5 cells were selected with G418 (1 mg/mL Geneti-
cin; Invitrogen) every other passage. Mini-genome experiments
were conducted under BSL-2 conditions. All work with infectious
virus, including rescue from cDNA, was done in a BSL-4 laboratory
in accordance with select agent regulations. Work with plasmids
88 L.S. Uebelhoer et al. / Antiviral Research 106 (2014) 86–94containing full-length genome sequences was performed in
accordance with approved Institutional Biosafety Committee
(IBC) protocols.
2.2. Plasmid construction and terminal sequencing of viral genomes
Support plasmids, mini-genomes, and infectious viruses
expressing gLuc were derived from previous constructs expressing
GFP, and have been described previously by our group (Albarino
et al., 2013; Towner et al., 2005). Codon-optimized genes for EBOV
were obtained from a commercial source (GenScript) and
subcloned into the standard Pol II expression plasmid, pCAGGS.
All support plasmids were codon-optimized for rodents.
2.3. Chemicals
Imatinib methanesulfonate salt (Gleevec) was purchased from
LC Laboratories. Ribavirin, chloroquine diphosphate, and 6-azauri-
dine were purchased from Sigma Life Science (Sigma–Aldrich).
20CMC, 20CMU, 20OMC, 20OMU, and 7-deaza-adenosine were
purchased from Carbosynth Limited. All chemicals were diluted
to a concentration of 100 mM prior to use, per manufacturers’
instructions.
2.4. Mini-genome expression and high-throughput analysis
Luciferase mini-genome experiments were carried out using the
same conditions as previously reported for a MARV GFP mini-
genome (Albarino et al., 2013). For high-throughput compound
screening experiments, BSR-T7/5 cells were split, washed, and
mixed with LT1 transfection reagent plus plasmids. 4  104 cells
were plated in 100 lL media per well, and compounds added at
2 concentration in an additional 100 lL media for a total
200 lL of media. For gLuc quantiﬁcation, 5 lL of supernatant was
harvested and transferred to a 96-well black ﬂat-bottom polysty-
rene plate (Corning Costar). 50 lL of luciferase reagent (1:100 mix-
ture of Luciferase Assay Substrate and Luciferase Assay Buffer;
Promega) was added to each well at a rate of 300 lL/s, and lumi-
nescence from the resultant reaction was read after a 2 s delay
using a monochromator-based multi-mode microplate reader
(BioTek Synergy™ H1MD, 10 ms integration, 100 gain/sensitivity).
To determine cell viability, supernatants were removed and 50 lL
of CellTiter-Glo Luminescent Cell Viability reagent added to each
well (Promega). Cells were lysed with gentle rocking for 10 min at
room temperature before transfer to a 96-well black ﬂat-bottom
polystyrene plate. ATP content was determined by reading
luminescence.
2.5. Calculating CC50, IC50, and SI50
The range of compound concentrations used in the high-
throughput mini-genome experiments was converted to a log
scale, and both luciferase expression and ATP content data were
graphed and subjected to 4-parameter, non-linear regression
analysis using GraphPad Prism software. The resulting CC50 (ATP
content) was divided by the IC50 (luciferase expression) to
determine the SI50 of each compound.
2.6. Rescue and characterization of infectious gLuc viruses
To generate infectious gLuc viruses, BHK-21 cells were transfec-
ted with full-length gLuc-containing genomes and support
plasmids, and the supernatants were applied to Vero-E6 cells fol-
lowing established protocols (Albarino et al., 2013). As previously
reported, all viruses used in these studies have a passage history
of 1 passage in BHK-21 cells and 2 passages in Vero-E6 cells.Aliquots of working viral stocks were fully sequenced, and small
aliquots were assayed for luciferase activity. To characterize gLuc
viruses, T25 ﬂasks of 70% conﬂuent Vero-E6 cells were infected
at an MOI of 0.1 using 0.5 mL of a 1:5 virus dilution in media. Virus
was allowed to adsorb for 1 h with gentle rocking. After adsorption,
monolayers were washed 3 times with PBS to eliminate any
residual virus. Supernatant aliquots were taken daily to determine
luciferase expression and viral titer by a standard TCID50 assay.
2.7. High-throughput analysis of inhibitors using infectious gLuc
viruses
To validate infectious gLuc viruses as a high-throughput system,
Vero-E6 cells were plated in 96-well plates overnight, and the next
day, media was removed and cells pre-treated for 1 h with 100 lL
media containing various concentrations of inhibitors. Virus was
added in an additional 100 lL media (ﬁnal MOI of 0.05). After
1.5 h, cells were washed 3 times with PBS and re-supplemented
with media containing inhibitors. 48 h post-infection, 5 lL of
supernatant was tested for luciferase expression and ATP content
as above.
2.8. Virus titration
Viruses were titrated using a standard 50% tissue culture infec-
tive dose (TCID50) protocol (Krahling et al., 2010; Neumann et al.,
2002). Brieﬂy, VeroE6 cells were seeded in 96-well plates, and
infected 24 h later using 10-fold dilutions (101 to 108) of the
virus samples. Each virus dilution was applied into a plate column;
therefore, each dilution was counted in 8 replica wells. Five days
later, cells were ﬁxed with formalin, permeabilized with Triton
0.1% and stained with either a rabbit anti-MARV or anti-EBOV
polyclonal antibody, followed by counter-staining with anti-rabbit
Alexaﬂuor 498 or 594 nm secondary antibodies (Molecular
Probes). The TCID50/ml was determined using the Reed and
Muench method.3. Results
To facilitate the screening of antivirals against EBOV and MARV,
we ﬁrst created a recombinant system in which gLuc expression is
controlled by mini-genome RNA replication and transcription. The
gLuc reporter gene was cloned between the viral 30 and 50 UTRs in
the negative-sense orientation into a standard T7 plasmid. Support
plasmids were created by cloning the open reading frames (ORFs)
of MARV and EBOV NP, VP35, VP30 and L into a standard Pol II
expression plasmid (Fig. 1B). Mini-genome activity was tested in
BSR-T7/5 cells stably expressing T7 RNA polymerase by transfect-
ing MARV or EBOV mini-genome plasmids, along with their
corresponding support plasmids. Thus, gLuc expression relies on
mini-genome replication (Fig. 1B), and gLuc is secreted from cells,
allowing for easy collection of supernatants at various times post-
transfection to quantify luciferase production (Fig. 1C). In these
experiments, gLuc expression was relatively low over background
(3-fold in MARV and 10-fold in EBOV), and plateaued four days
post-transfection (Fig. 1C, left panels). The relatively high signal
from the negative control that contains no polymerase support
plasmid is most likely due to positive-sense transcripts started
on cryptic RNApol II promoters present in many plasmid
backbones and/or related to the enzymatic nature of the reporter
gene. Indeed, this is not an unusual problem and it has been
addressed using different approaches by others (Groseth et al.,
2005; Jasenosky et al., 2010). However, it should be noted that
multiple groups have successfully used MARV and EBOV mini-
genome systems supported by wild-type plasmids in multiple
Fig. 2. High-throughput screen of RNA replication inhibitors using gLuc mini-genomes. (A) BSR-T7/5 cells were trypsinized, transfected with mini-genomes plus codon-
optimized support plasmids, and plated in 96-well plates with compounds at indicated concentrations. 5 lL of supernatant was assayed for luciferase expression of EBOV
(right panels) and MARV (left panels) mini-genome plasmids. Data is representative of 2 independent experiments; mean and SEM of luciferase expression from 4 wells is
depicted as bars (left Y-axis). Cell monolayers were lysed immediately after luciferase quantiﬁcation and assayed for ATP content (circles, right Y-axis). Background luciferase
activity observed in transfected cells lacking virus polymerase activity (e.g., transfected with the empty vector control pCAGGS) is denoted by a dotted line (——). (B)
Reduction of luciferase signal by each compound at the highest tested non-toxic concentration. Numbers represent percentage of reduction compared to non-treated cells
replicating mini-genomes. (C) 50% cytotoxic concentration (CC50), 50% inhibitory concentration (IC50), and 50% selectivity index (SI50) of each compound were calculated as
described in methods.
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Fig. 3. Rescue and characterization of infectious rMARV/Luc and rEBOV/Luc viruses. (A) Schematic representation of gLuc-expressing ﬁlovirus genomes. (B) Characterization
of rMARV/Luc and rEBOV/Luc viruses. Vero-E6 cells were infected with rMARV/Luc or rEBOV/Luc at an MOI of 0.1, and supernatants collected up to 5 d post-infection and
frozen at80 C. After thawing, samples were divided and used to determine luciferase expression (bars, right Y-axis, duplicate reads) or viral titer using TCID50 assay (circles,
left Y-axis). Note the accelerated luciferase and virion production (1 log and 2 logs increase, respectively) in rEBOV/Luc at 1 d post-infection compared to rMARV/Luc.
90 L.S. Uebelhoer et al. / Antiviral Research 106 (2014) 86–94mammalian cell types including hamster-derived cells (Boehmann
et al., 2005; DiCarlo et al., 2007; Groseth et al., 2005, 2007; Hoenen
et al., 2011; Jasenosky et al., 2010; Moller et al., 2005; Muhlberger
et al., 1998, 1999; Prins et al., 2010; Schumann et al., 2009;
Trunschke et al., 2013; Wenigenrath et al., 2010).
To improve signal, wild-type viral genes in support plasmids
were codon-optimized for rodents to match the species origin of
our target cells. Plasmids were then co-transfected with the origi-
nal gLuc mini-genomes, and sampled as before. This approach
resulted in an approximately 2000-fold increase of signal-to-
background ratios, and high, sustained gLuc expression easily
detectable in <5 lL of harvested supernatant starting 24 h post-
transfection in both EBOV andMARV systems (Fig. 1C, right panels;
Supporting Fig. 1).
Previous efforts to screen anti-ﬁlovirus compounds have report-
edly been hindered by the lack of high-throughput quantitative
reporter systems that can be used in a BSL-2 setting [see (Hoenen
et al., 2011) for review]. To address this limitation, we evaluated
the potential of the codon-optimized gLuc mini-genome systems
to function in a high-throughput 96-well format. In our initial
experiments, BSR-T7/5 cells were grown in 12-well plates (low
throughput) and transfected with either EBOV or MARV mini-
genome plasmids and sampled 24 h and 48 h post-transfection to
measure gLuc expression. Z0 values, a measure of well-to-well
variability, were calculated and found to be 0.52 for both EBOV
and MARV. Assays with Z0 values >0.5 are considered higher qual-
ity, with replicate variability decreasing as Z0 values approach 1
(Zhang et al., 1999). To adapt this system to a high-throughput
format, BSR-T7/5 cells were trypsinized, washed, mixed with the
appropriate plasmids and transfection reagent, and plated in a
96-well plate. Interestingly, MARV mini-genome replication lags
slightly behind EBOV mini-genome replication regardless of the
format (see Fig. 1C, right panels, for low-throughput example).
For this reason, we chose 48 h post-transfection as the standard-
ized sampling time for future work using high throughput mini-
genome systems. Z0 values were re-calculated for the 96-well
format and were found to not signiﬁcantly change for either MARV
(0.48) or EBOV (0.56).
To test the high-throughput mini-genome gLuc reporter sys-
tems, we screened ribavirin (Ribv) and several nucleoside ana-
logs, each with known antiviral activities against other viruses.
BSR-T7/5 cells were transfected with gLuc mini-genomes andoptimized support plasmids and plated in a 96-well format in
growth media containing each compound at various concentra-
tions (Fig. 2; Supporting Fig. 1). The 50% cytotoxicity concentra-
tion (CC50; determined by cellular ATP content), inhibitory
concentration (IC50; determined by luciferase expression), and
selectivity index (SI50) were then calculated (see Section 2). In
both MARV and EBOV systems, several compounds inhibited viral
replication at concentrations that showed low cellular toxicity
(Fig. 2). 80 lM Ribv reduced luciferase signal by 96% for MARV
and 71% for EBOV, and 40 lM 6-azauridine (6azaU) reduced lucif-
erase signal by 99% for MARV and 81% for EBOV (Fig. 2B). Speciﬁc
signal reduction by Ribv corresponds to SI50 of 19 for MARV and 8
for EBOV, while SI50 of 6azaU was 17 for MARV and 16 for EBOV
(Fig. 2C). Several compounds, such as 20-C-methylcytidine
(20CMC), showed negligible SI50 indices in both systems, with
decreases in luciferase signal due to cell death (Fig. 2A).
20-O-methylcytidine (20OMC), 20-O-methyluridine (20OMU),
20-C-methyluridine (20CMU), and 7-deaza-adenosine were tested
in the MARV mini-genome system, but showed negligible
inhibition (data not shown).
Next, we tested candidate compounds on infectious MARV and
EBOV to determine whether compounds that inhibit mini-genome
replication also inhibit infectious virus. Previous approaches used
wild-type, GFP-expressing or Fireﬂy luciferase-expressing EBOV
in the presence of candidate antivirals, and measured viral growth
by standard TCID50 assay, qRT-PCR (following RNA extraction),
GFP, or luciferase signal. However, each of these approaches has
various drawbacks such as lengthy multi-step assays, limited
dynamic range or required destruction of infected cell monolayers
(Hoenen et al., 2013). For these reasons, we constructed recombi-
nant viruses expressing gLuc to allow a rapid, real-time assessment
of viral replication over an 8-log range from repeated small
aliquots (1–5 lL) of infected cell supernatants.
Brieﬂy, full-length genomes of MARV and EBOV containing the
gLuc reporter gene, rMARV/Luc and rEBOV/Luc, respectively, were
cloned in viral complementary orientation into a standard T7 tran-
scription plasmid, similar to that used to generate GFP-expressing
ﬁloviruses (Albarino et al., 2013; Towner et al., 2005) (Fig. 3A).
Using optimized ratios of support plasmids and plasmids contain-
ing the full-length genomes, gLuc-containing viruses were rescued
and stocks grown to high titers. For each virus, we measured viral
growth kinetics by standard TCID50 assay, and compared these
Fig. 4. High-throughput screen of candidate antiviral compounds using rMARV/Luc and rEBOV/Luc viruses. (A) Uninfected Vero-E6 cells were treated with compounds at the
indicated concentration and assayed for cytotoxicity. (B) Vero-E6 cells in 96-well plates were pre-treated with compounds at indicated concentrations for 1 h, and then
infected with rMARV/Luc or rEBOV/Luc at an MOI of 0.05. 48 h post-infection, 5 lL supernatant samples were assayed for luciferase expression (bars); cells were lysed
immediately afterwards to determine ATP content (circles). Mean and SEM of 4 wells are displayed. (C) Reduction of luciferase signal compared to untreated cells was
calculated for each compound at the indicated concentrations.
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Fig. 5. Conﬁrmation of candidate antiviral compound activity using wild-type MARV and EBOV. (A) Vero-E6 cells were pre-treated with compounds at the highest
concentrations used in Fig. 4, and infected with 0.5 MOI wild-type MARV or EBOV. Supernatants were collected 48 h post-infection, and viral titers were determined by TCID50
assay. (B) Percent reduction in viral titers after treatment with indicated compounds compared to untreated cells.
92 L.S. Uebelhoer et al. / Antiviral Research 106 (2014) 86–94values to luciferase production measured at the same time points.
Our data show that luciferase activity closely mirrors virus
production in rMARV/Luc. From 0 to 1 d post-infection, luciferase
production increased 200-fold while TCID50 values increased
2000-fold. From 1 to 2 d post-infection, the respective increases
for both methods were 80-fold (Fig. 3B, left panel). For rEBOV/
Luc, luciferase expression and virus production were nearly
identical: luciferase levels increased 5000-fold and 20-fold from
day 0 to 1 and 1 to 2, respectively, while TCID50 values increased
10,000-fold and 30-fold over the same interval (Fig. 3B, right
panel).
After conﬁrming that luciferase expression paralleled virus
production, we tested compounds for antiviral activity using
infectious gLuc viruses. Ribv and 6azaU, which effectively inhib-
ited mini-genome replication, were tested, along with several
compounds previously shown to be effective anti-ﬁloviral agents
(Garcia et al., 2012; Madrid et al., 2013). Initially, uninfected
Vero-E6 cells were treated with each compound using a wide
range of concentrations, and assayed for cell viability to deter-
mine the maximum concentration tolerated without toxicity
(Fig. 4A). Then, cells were pre-treated with concentrations below
this value and infected at a low MOI with either rMARV/Luc or
rEBOV/Luc viruses. Supernatants were collected 48 h post-
infection and luciferase production was measured. The data show
6azaU, chloroquine, and Gleevec (Imatinib methanesulfonate
salt) all signiﬁcantly reduced signal by 90–95%, >99%, and 98–
99%, respectively (Fig. 4B). Ribv however, had very little effect
on virus growth even at 1280 lM, the highest concentration
tested (Fig. 4B), contrasting the reduction observed with the
mini-genome system (Fig. 2). These results with infectious virus
are consistent with previous studies of EBOV in in vitro and
in vivo models (Huggins, 1989; Ignatyev et al., 2000). The ribavi-
rin data were included here to highlight the fact that while mini-
genome systems can be very useful for initial antiviral screens at
BSL-2, the results do not always translate to that observed with
infectious virus. A minor difference between the minigenome
and infectious virus assays worth noting is that in the infectious
virus assays, cells were pre-treated one hour before virus infec-
tion whereas in the minigenome assays, compounds were added
at the time of transfection.To conﬁrm that the effects of the selected compounds were not
speciﬁc to gLuc-expressing viruses, we re-tested the same
compounds on wild-type MARV and EBOV using the highest
concentrations shown in Fig. 4. As before, Ribv had no effect on
wt EBOV and had only a modest effect on wt MARV (Fig. 5A and
B) while 6azaU, chloroquine, and Gleevec all reduced MARV and
EBOV growth by >95%, as assessed by TCID50 assay (Fig. 5A; % titer
reduction summarized in Fig. 5B). Overall, gLuc-expressing ﬁlovi-
ruses grew similarly to wild-type viruses, and generally proved a
faithful extension of our gLuc mini-genome results, although not
always as demonstrated by the ribavirin studies. Importantly, gLuc
results were obtained 3 times faster than results from wild-type
virus (2–3 days versus 7–9 days, respectively), demonstrating the
advantage of screening compounds using a luciferase-based
readout rather than traditional titration methods.
As further conﬁrmation that these systems can be used to
screen inhibitors of ﬁlovirus RNA replication, we tested several
small interfering RNAs (siRNAs) in the MARV gLuc mini-genome
and rMARV/Luc infectious virus platforms. siRNAs have been
shown previously to block ﬁlovirus and arenavirus replication
(Fowler et al., 2005; Geisbert et al., 2006), including ones that tar-
get the 50 and 30 UTRs (Groseth et al., 2007; Muller and Gunther,
2007). Here, siRNAs targeting both the 50 and 30 UTRs of MARV
were co-transfected into BSR-T7/5 cells with the MARV gLuc
mini-genome and support plasmids. Two siRNAs targeting the
30UTR were able to inhibit luciferase expression >90% compared
to mock-transfected cells (Supporting Fig. 2A). These siRNAs were
also able to inhibit luciferase activity of rMARV/Luc, showing
75–90% reduction over mock-transfected cells (Supporting
Fig. 2B). The siRNAs targeting the 50UTR showed no inhibitory
activity (data not shown). These results suggest that both mini-
and infectious gLuc systems can be used to screen siRNA inhibitors
in addition to antiviral compounds, thus extending their potential
utility.
4. Discussion
Together, the platforms presented here form a complementary
approach to screen candidate antivirals targeting ﬁloviruses. The
gLuc mini-genome platform was used to identify potential
L.S. Uebelhoer et al. / Antiviral Research 106 (2014) 86–94 93inhibitors of viral replication, and gLuc viruses conﬁrmed in some
cases inhibitor activity and identiﬁed additional agents inhibiting
other stages of the virus life cycle. The gLuc mini-genome plat-
form produces more rapid results (<48 h) than some previous
low-containment screening approaches, such as chloramphenicol
acetyltransferase (Muhlberger et al., 1998, 1999) or GFP (Groseth
et al., 2005) reporter genes. The gLuc infectious virus platform is
also rapid, although it remains restricted to BSL-4 containment.
rMARV/Luc is the ﬁrst of its kind, while rEBOV/Luc is similar to
a recently described Fireﬂy luciferase-expressing virus (Hoenen
et al., 2013). In general, luciferase-expressing viruses are a signif-
icant improvement over earlier, less quantitative GFP or RFP-
expressing viruses (Ebihara et al., 2007; Schmidt et al., 2011;
Schudt et al., 2013; Towner et al., 2005) that require high-content
sophisticated imaging techniques (Panchal et al., 2010, 2012).
Moreover, both gLuc-expressing platforms presented here
improve on previous Fireﬂy or Renilla luciferase-based platforms
(Filone et al., 2013; Jasenosky et al., 2010; Krahling et al., 2010;
Schumann et al., 2009; Wenigenrath et al., 2010) because low
volumes (1–5 lL) of supernatant samples can be collected at
multiple time points without affecting cell viability. Both mini-
genome and infectious virus platforms are easily adapted to a
96-well, high-throughput format without compromising overall
robustness (assessed by Z0 value).
Using the dual-platform methodology, we have identiﬁed
6azaU, a compound that suppresses de novo pyrimidine biosyn-
thesis (Handschumacher, 1960), as a potent inhibitor of both
MARV and EBOV mini-genomes and infectious viruses. This
compound has broad-spectrum antiviral activity in vitro, partic-
ularly against pathogenic viruses (Crance et al., 2003; Morrey
et al., 2002; Pyrc et al., 2006; Smee et al., 1987). We have addi-
tionally demonstrated that gLuc viruses can serve as a stand-
alone approach for identifying inhibitors of viral life cycle
stages besides RNA replication. Chloroquine and Gleevec, two
previously identiﬁed effective anti-EBOV agents (Garcia et al.,
2012; Madrid et al., 2013), reduced virus luciferase signal by
>98%, and these results were conﬁrmed using wild-type non-
reporter viruses measured by traditional assays. Combining
these compounds with one another, or with other therapeutic
approaches like siRNA or neutralizing antibodies, may produce
an enhanced synergistic effect.
To our knowledge, ours are the ﬁrst mini-genome and
infectious ﬁlovirus systems expressing a secreted gLuc reporter
[see (Hoenen et al., 2011) for review] and the only description of
recombinant MARV expressing luciferase. The possibility of using
mini-genomes in a low-containment setting should signiﬁcantly
expand the number of institutions able to conduct anti-ﬁlovirus
agent screens. Although the compounds we tested may be speciﬁc
to the strains of MARV and EBOV presented here, the methodolo-
gies could easily be adapted to other ﬁloviruses.Acknowledgments
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